» Articles » PMID: 38032570

Sex Differences in the Clinical Presentation and Natural History Of Dilated Cardiomyopathy

Abstract

Background: Biological sex has a diverse impact on the cardiovascular system. Its influence on dilated cardiomyopathy (DCM) remains unresolved.

Objectives: This study aims to investigate sex-specific differences in DCM presentation, natural history, and prognostic factors.

Methods: The authors conducted a prospective observational cohort study of DCM patients assessing baseline characteristics, cardiac magnetic resonance imaging, biomarkers, and genotype. The composite outcome was cardiovascular mortality or major heart failure (HF) events.

Results: Overall, 206 females and 398 males with DCM were followed for a median of 3.9 years. At baseline, female patients had higher left ventricular ejection fraction, smaller left ventricular volumes, less prevalent mid-wall myocardial fibrosis (23% vs 42%), and lower high-sensitivity cardiac troponin I than males (all P < 0.05) with no difference in time from diagnosis, age at enrollment, N-terminal pro-B-type natriuretic peptide levels, pathogenic DCM genetic variants, myocardial fibrosis extent, or medications used for HF. Despite a more favorable profile, the risk of the primary outcome at 2 years was higher in females than males (8.6% vs 4.4%, adjusted HR: 3.14; 95% CI: 1.55-6.35; P = 0.001). Between 2 and 5 years, the effect of sex as a prognostic modifier attenuated. Age, mid-wall myocardial fibrosis, left ventricular ejection fraction, left atrial volume, N-terminal pro-B-type natriuretic peptide, high-sensitivity cardiac troponin I, left bundle branch block, and NYHA functional class were not sex-specific prognostic factors.

Conclusions: The authors identified a novel paradox in prognosis for females with DCM. Female DCM patients have a paradoxical early increase in major HF events despite less prevalent myocardial fibrosis and a milder phenotype at presentation. Future studies should interrogate the mechanistic basis for these sex differences.

Citing Articles

Systematic Review, Meta-Analysis, and Population Study to Determine the Biologic Sex Ratio in Dilated Cardiomyopathy.

Bergan N, Prachee I, Curran L, McGurk K, Lu C, de Marvao A Circulation. 2025; 151(7):442-459.

PMID: 39895490 PMC: 11827689. DOI: 10.1161/CIRCULATIONAHA.124.070872.


Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations.

Sorella A, Galanti K, Iezzi L, Gallina S, Mohammed S, Sekhri N Eur Heart J Qual Care Clin Outcomes. 2024; 11(2):206-222.

PMID: 39674807 PMC: 11879293. DOI: 10.1093/ehjqcco/qcae109.


Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine.

Gigli M, Stolfo D, Merlo M, Sinagra G, Taylor M, Mestroni L Nat Rev Cardiol. 2024; 22(3):183-198.

PMID: 39394525 DOI: 10.1038/s41569-024-01074-2.


Hearts apart: sex differences in cardiac remodeling in health and disease.

Martin T, Leinwand L J Clin Invest. 2024; 134(13).

PMID: 38949027 PMC: 11213513. DOI: 10.1172/JCI180074.


Navigating the penetrance and phenotypic spectrum of inherited cardiomyopathies.

Serpa F, Finn C, Tahir U Heart Fail Rev. 2024; 29(5):873-881.

PMID: 38898187 DOI: 10.1007/s10741-024-10405-x.

References
1.
Gammill H, Chettier R, Brewer A, Roberts J, Shree R, Tsigas E . Cardiomyopathy and Preeclampsia. Circulation. 2018; 138(21):2359-2366. DOI: 10.1161/CIRCULATIONAHA.117.031527. View

2.
Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz H . A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020). Pharmacoeconomics. 2020; 38(11):1219-1236. PMC: 7546989. DOI: 10.1007/s40273-020-00952-0. View

3.
de Marvao A, McGurk K, Zheng S, Thanaj M, Bai W, Duan J . Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021; 78(11):1097-1110. PMC: 8434420. DOI: 10.1016/j.jacc.2021.07.017. View

4.
Alba A, Gaztanaga J, Foroutan F, Thavendiranathan P, Merlo M, Alonso-Rodriguez D . Prognostic Value of Late Gadolinium Enhancement for the Prediction of Cardiovascular Outcomes in Dilated Cardiomyopathy: An International, Multi-Institutional Study of the MINICOR Group. Circ Cardiovasc Imaging. 2020; 13(4):e010105. DOI: 10.1161/CIRCIMAGING.119.010105. View

5.
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P . Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2007; 29(2):270-6. DOI: 10.1093/eurheartj/ehm342. View